Oppositional Defiant Disorder | Defiant Teenager | Defiant Kid | ADHD

Back to ADHD News List

New River Pharmaceuticals And Shire Receive Approvable Letter For VYVANSE lisdexamfetamine Dimesylate For The Treatment Of ADHD

New River Pharmaceuticals Inc. (NASDAQ: NRPH) and its collaborative partner Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today that the U.S. Food and Drug Administration (FDA) has issued a second approvable letter for VYVANSE (lisdexamfetamine dimesylate, formerly known as NRP104) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). [click link for full article]

Source: http://www.medicalnewstoday.com/sections/adhd/

In schools, treatment plans are often poorly integrated. In addition, there are few special education funds directed specifically for ADHD
 

This page is about Attention deficit hyperactivity disorder (ADHD)